Recommendation From Pharmaceuticals and Finance Sector
![]()
DSIJ selects two aggressive stock picks in every issue, with a 15 day horizon based upon the bullish trend during that period. For this issue, we are recommending companies from Pharmaceuticals and Finance Sector.
Alankit
CMP: 147
BSE Code: 531082
Volume: 76731
Face Value: 2
Alankit’s business includes selling or buying or subscribing to or dealing in shares and also commodities trading business and its related correspondence activities. It also provides advisory and consultancy services. The company’s board of directors recommended issue of bonus shares in the proportion of 1:1. It has also considered and approved the sub division of one equity share of face value of Rs 2 into two equity shares of Rs 1 each. On segmental revenue front, Alankit has earned 88.32 per cent from e-governance and remaining 11.68 per cent from e-governance trading during FY16. The company posted revenue of Rs 13.13 crore in Q1FY17 against Rs 14.46 crore in Q4FY16. Its EBITDA remained at Rs 2.85 crore in Q1FY17 while Rs 4.4 crore in Q4FY16. The services related to Commercial Taxes Facilitation Centres (CTFC), Uttar Pradesh Commercial Taxes Department has been transferred from M/s Alankit Assignments to the company.
Suven Life Sciences
CMP: 190
BSE Code: 530239
Volume: 57727
Face Value: 1
Suven Life Sciences is a bio-pharmaceutical company. The company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. During September month, it has secured two product patents in India and Japan. Suven Life Sciences also received three product patents in Canada, Europe and Hong Kong. During Q1FY17, the company locked up 11 product patents covering India, South Africa, Israel, Mexico, Canada, Honk Kong, Europe, Eurasia, Macau and New Zealand. Its Pashamylaram unit successfully completed USFDA inspection. On financial front, Suven Life Sciences’ top line increased by 29.54 per cent to Rs 138 in Q1FY17 as compared to same period in previous fiscal year. The company’s EBITDA too boosted by 56.34 to Rs 47.93 crore in Q1FY17 on a yearly basis. Its PAT also increased by 58.12 per cent to Rs 32.58 crore in Q1F17 as compared to the same period in the previous fiscal year.